2. Search Result
Search Result
Results for "

eye disease

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

1

Fluorescent Dye

2

Biochemical Assay Reagents

1

Peptides

2

Inhibitory Antibodies

2

Natural
Products

3

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132596A
    Tivanisiran sodium

    SYL1001 sodium

    		 TRP Channel Neurological Disease
    Tivanisiran sodium is a siRNA used for the study of dry eye disease. Tivanisiran sodium was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA .
    Tivanisiran sodium
  • HY-P99009
    Batoclimab

    RVT-1401; HBM9161; IMVT-1401

    		 Fc Receptor (FcR) Inflammation/Immunology
    Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease .
    Batoclimab
  • HY-150069
    UBX1325

    		Bcl-2 Family Apoptosis Metabolic Disease
    UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .
    UBX1325
  • HY-120417
    JP-153

    		Src FAK Cardiovascular Disease
    JP-153 is the Src-FAK-Paxillin signaling inhibitor. JP-153 inhibits Src-dependent phosphorylation of paxillin (Y118) and downstream activation of Akt (S473). JP-153 reduces VEGF-induced migration and proliferation in retinal endothelial cells. JP-153 can be uesd for the study of neovascular eye disease .
    JP-153
  • HY-117661
    SPHINX31
    Maximum Cited Publications
    9 Publications Verification

    		 SRPK VEGFR Cardiovascular Disease Cancer
    SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC50 of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A165a isoform. SPHINX31 can be used to research neovascular eye disease .
    SPHINX31
  • HY-152264
    CFTR activator 1

    		CFTR Inflammation/Immunology
    CFTR activator 1 is a potent and selective CFTR activator, with an EC50 of 23 nM. CFTR activator 1 can be used to ameliorate dry eye disease .
    CFTR activator 1
  • HY-P991134
    Elegrobart

    		IGF-1R Inflammation/Immunology
    Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
    Elegrobart
  • HY-132596
    Tivanisiran

    SYL1001

    		 Small Interfering RNA (siRNA) TRP Channel Neurological Disease
    Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA .
    Tivanisiran
  • HY-W281862
    Sequifenadine

    		Histamine Receptor Inflammation/Immunology
    Sequifenadine is a H1-antihistamine. Sequifenadine has the potential for the research of inflammatory eye disease with allergic symptoms .
    Sequifenadine
  • HY-153565
    Immune cell migration-IN-1

    		Others Inflammation/Immunology
    Immune cell migration-IN-1 (compound 2) is a potent agent to inhibit immune cell migration. Immune cell migration-IN-1 can be used for research in alleviating dry eye diseases, eczema dermatitis and psoriasis .
    Immune cell migration-IN-1
  • HY-19344
    Lifitegrast
    5 Publications Verification

    SAR 1118; SHP-606

    		 Integrin Inflammation/Immunology
    Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast
  • HY-19344A
    Lifitegrast sodium
    5 Publications Verification

    SAR 1118 sodium; SHP-606 sodium

    		 Integrin Inflammation/Immunology
    Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .
    Lifitegrast sodium
  • HY-19344R
    Lifitegrast (Standard)

    		Integrin Inflammation/Immunology
    Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast (Standard)
  • HY-147240
    Acloproxalap

    ADX-629

    		 Others Infection Cardiovascular Disease Inflammation/Immunology
    Acloproxalap is a quinoline-based aldehyde scavenger that can be used in studies of diseases with toxic aldehyde accumulation, such as inflammatory diseases of the eye and skin, respiratory diseases such as pneumonia, organ diseases, and viral infection-related syndromes .
    Acloproxalap
  • HY-P10904
    Vezocolmitide

    		Collagen Others
    Vezocolmitide is a collagen mimetic peptide and is the component of ST-100. Vezocolmitide can be used for research of dry eye disease (DED) .
    Vezocolmitide
  • HY-B0606
    Diquafosol tetrasodium
    5 Publications Verification

    INS365

    		 P2Y Receptor Inflammation/Immunology
    Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.
    Diquafosol tetrasodium
  • HY-W751874
    Acetyl methylene blue

    		Mitochondrial Metabolism Neurological Disease
    Acetyl methylene blue can be used to synthesize mitochondrial development stimulators, which can be used for eye diseases related to insufficient mitochondrial function in nerve cells .
    Acetyl methylene blue
  • HY-W354753
    Homatropine hydrochloride

    		mAChR Others
    Homatropine hydrochloride is an orally active anticholinergic agent that rapidly dilates pupils and has cycloplegic effects. Homatropine hydrochloride also has antitussive activity. Homatropine hydrochloride can be used in research on eye diseases and coughs .
    Homatropine hydrochloride
  • HY-B0535R
    Ethambutol (Standard)

    		Bacterial Antibiotic Infection
    Homatropine (hydrochloride) (Standard) is the analytical standard of Homatropine (hydrochloride). This product is intended for research and analytical applications. Homatropine hydrochloride is an orally active anticholinergic agent that rapidly dilates pupils and has cycloplegic effects. Homatropine hydrochloride also has antitussive activity. Homatropine hydrochloride can be used in research on eye diseases and coughs .
    Ethambutol (Standard)
  • HY-W354753R
    Homatropine (hydrochloride) (Standard)

    		mAChR Others
    Homatropine (hydrochloride) (Standard) is the analytical standard of Homatropine (hydrochloride). This product is intended for research and analytical applications. Homatropine hydrochloride is an orally active anticholinergic agent that rapidly dilates pupils and has cycloplegic effects. Homatropine hydrochloride also has antitussive activity. Homatropine hydrochloride can be used in research on eye diseases and coughs .
    Homatropine (hydrochloride) (Standard)
  • HY-B0321
    Tropicamide
    4 Publications Verification

    Ro 1-7683

    		 mAChR Neurological Disease
    Tropicamide (Ro 1-7683) is a selective M4 muscarinic acetylcholine receptor antagonist. When used as an eye drop, Tropicamide causes short-term mydriasis (pupil dilation) and cycloplegia. Tropicamide can be used in the research of neurological diseases, such as epilepsy .
    Tropicamide
  • HY-154994
    JAK-IN-30

    		JAK Inflammation/Immunology
    JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED) .
    JAK-IN-30
  • HY-B1035C
    ent-Levobunolol hydrochloride

    (R)-Bunolol hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease
    ent-Levobunolol (hydrochloride) ((R)-Bunolol (hydrochloride)) is a competitive β-adrenergic receptor blocker. ent-Levobunolol (hydrochloride) inhibits the transmission of sympathetic nerve impulses, reduces the production of aqueous humor, and constricts blood vessels in the eye, thereby reducing intraocular pressure. ent-Levobunolol (hydrochloride) is promising for research of ocular hypertension diseases such as glaucoma .
    ent-Levobunolol hydrochloride
  • HY-101990
    IMS2186

    		VEGFR Others
    IMS2186 is an anti-choroidal neovascularization (CNV) agent that inhibits angiogenesis upstream of VEGF. IMS2186 can arrest cancer cell cycle in G2/M phase, thus exerting anti-proliferation and anti-angiogenesis effects. IMS2186 has no intraocular toxicity and reduces the amount of eye leakage and diseased cells .
    IMS2186
  • HY-32067
    Aceclidine

    Quinuclidin-3-yl acetate

    		 mAChR Cardiovascular Disease Neurological Disease
    Aceclidine (Quinuclidin-3-yl acetate) is a modulator of M3 muscarinic acetylcholine receptor and a M1 receptor agonist (EC50: 40 μM). Aceclidine is a cycloplegic agent, a surfactant, a tonicity adjustor and optionally a viscosity enhancer and an antioxidant. Aceclidine has the potential for the research of disorders such as refractive errors of the eye, xerostomia, Sjogren's syndrome, glaucoma, conjunctivitis, lacrimal gland disease, and esotropia .
    Aceclidine
  • HY-N0188
    Esculin
    4 Publications Verification

    		 p38 MAPK Inflammation/Immunology Cancer
    Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .
    Esculin
  • HY-32067A
    Aceclidine hydrochloride

    Quinuclidin-3-yl acetate hydrochloride

    		 mAChR Neurological Disease
    Aceclidine (Quinuclidin-3-yl acetate) hydrochloride is a modulator of M3 muscarinic acetylcholine receptor and a M1 receptor agonist (EC50: 40 μM). Aceclidine hydrochloride is a cycloplegic agent, a surfactant, a tonicity adjustor and optionally a viscosity enhancer and an antioxidant. Aceclidine hydrochloride has the potential for the research of disorders such as refractive errors of the eye, xerostomia, Sjogren's syndrome, glaucoma, conjunctivitis, lacrimal gland disease, and esotropia .
    Aceclidine hydrochloride
  • HY-112352
    SU9518

    		Endogenous Metabolite Others
    SU9518 is a tyrosine kinase inhibitor with specific activity against PDGFRα. SU9518 can inhibit the development of proliferative vitreoretinopathy (PVR) in fibroblast and Muller cell rabbit models. SU9518 showed effective inhibitory effects in these models without toxic effects. Therefore, SU9518 has the potential to be used to inhibit PVR in humans and other proliferative eye diseases involving fibrosis and gliosis .
    SU9518
  • HY-N0188R
    Esculin (Standard)

    		p38 MAPK Inflammation/Immunology Cancer
    Esculin (Standard) is the analytical standard of Esculin. This product is intended for research and analytical applications. Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .
    Esculin (Standard)
  • HY-19344S2
    Lifitegrast-d4-1

    		Isotope-Labeled Compounds Integrin Inflammation/Immunology
    Lifitegrast-d4-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast-d4-1
  • HY-153567
    Immune cell migration-IN-2

    		Biochemical Assay Reagents Inflammation/Immunology
    Immune cell migration-IN-2 is a potent immune cell migration inhibitor with an EC50 of 13.5 nM in a T-cell adhesion assay. Immune cell migration-IN-2 is extracted from patent WO2019001171, example 11, can be used for dry-eye and other retinal diseases research . Immune cell migration-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Immune cell migration-IN-2
  • HY-19344S1
    Lifitegrast-d6

    SAR 1118-d6; SHP-606-d6

    		 Isotope-Labeled Compounds Inflammation/Immunology
    Lifitegrast-d6 (SAR 1118-d6) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast-d6
  • HY-19344S
    Lifitegrast-d4

    SAR 1118-d4; SHP-606-d4

    		 Isotope-Labeled Compounds Inflammation/Immunology
    Lifitegrast-d4 (SAR 1118-d4) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
    Lifitegrast-d4
  • HY-160637
    Lp-PLA2-IN-17

    		Phospholipase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA2. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA2 .
    Lp-PLA2-IN-17